Search Within

Gunjan Lalitchandra Shah

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (155)
  2. Journal Article (71)
  3. Research Letter (7)
  4. Correspondence (2)
Groups
  1. Biostatistics Service (235)
  2. Bone Marrow Transplant (235)
  3. Center for Hematologic Malignancies (235)
  4. Department of Medicine (235)
  5. Epidemiology and Biostatistics (235)
  6. Hematologic Malignancies, Division of (235)

More Groups

People
  1. Sergio Giralt (195)
  2. Michael Scordo (181)
  3. Sean Devlin (177)
  4. Miguel-Angel Perales (134)
  5. Parastoo Dahi (108)
  6. Heather Landau (98)

More People

Years
  1. 2025 (9)
  2. 2024 (28)
  3. 2023 (48)
  4. 2022 (31)
  5. 2021 (19)
  6. 2020 (33)

More Years

Publications
  1. Blood (70)
  2. Biology of Blood and Marrow Transplantation (43)
  3. Clinical Lymphoma, Myeloma and Leukemia (24)
  4. Bone Marrow Transplantation (17)
  5. Blood Advances (14)
  6. Transplantation and Cellular Therapy (13)

More Publications

Publishers
  1. American Society of Hematology (84)
  2. Elsevier Inc. (83)
  3. Nature Publishing Group (26)
  4. American Society of Clinical Oncology (9)
  5. Taylor & Francis Group (7)
  6. American Association for Cancer Research (5)

More Publishers

Results (235)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Research Letter

    Korde, N.; Mastey, D.; Tavitian, E.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Shah, U.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • The International Prognostic Index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy
    Journal Article

    Garcia-Recio, M.; Wudhikarn, K.; Pennisi, M.; Alonso-Trillo, R.; Flynn, J.; Shouval, R.; Afuye, A. O.; Silverberg, M. L.; Batlevi, C. W.; Dahi, P.; more...
    Transplantation and Cellular Therapy (2021)

    Fulltext@MSK | Save
  • Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: A multicenter observational study
    Journal Article

    Khan, N.; Lindner, S.; Gomes, A. L. C.; Devlin, S. M.; Shah, G. L.; Sung, A. D.; Sauter, C. S.; Landau, H. J.; Dahi, P. B.; Perales, M. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma
    Research Letter

    Lin, R. J.; Lobaugh, S. M.; Pennisi, M.; Chan, H. T.; Batlevi, Y.; Ruiz, J. D.; Elko, T. A.; Maloy, M. A.; Batlevi, C. L.; Dahi, P. B.; more...
    Haematologica (2021)

    Fulltext@MSK | Save
  • VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup
    Meeting Abstract

    Tan, C.; Diamond, B.; Hultcrantz, M.; Korde, N.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Patel, D.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)
    Meeting Abstract

    Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Rabbit anti-thymocyte globulin exposure (rATG) in CD34+ selected hematopoietic cell transplantation and its impact on immune reconstitution and outcomes in children and adults
    Meeting Abstract

    Lakkaraja, M.; Scordo, M.; Mauguen, A.; Cho, C.; Devlin, S.; Avecilla, S. T.; Boulad, F.; Cancio, M. I.; Curran, K. J.; Jakubowski, A. A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Association of patient activity bioprofiles with Hrqol and clinical responses: A prospective novel trial using mobile wearables in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Korde, N.; Tavitian, E.; Derkach, A.; Zarski, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save